The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.
Patient is male and aged >18 years old.
Biopsy proven prostate adenocarcinoma.
Patients electing to undergo Radical Prostatectomy (RP) with Pelvic lymph node dissection (PLND).
ECOG performance status 0-2; expected survival ≥ 6 months.
1. Participants who have previously participated in other interventional clinical trials and are within five physical half-lives, or have received radionuclide agents previously with an interval of less than ten physical half-lives prior to study drug injection.
Single group
68-Ga-NYM032
DrugIV injection
sensitivity and specificity
Assessing the sensitivity and specificity of 68Ga-NYM032 Injection positron emission tomography (PET) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
